Professional Documents
Culture Documents
Effects of Drugs On Clinical Laboratory Tests DS Young
Effects of Drugs On Clinical Laboratory Tests DS Young
Effects of Drugs On Clinical Laboratory Tests DS Young
Drugs on
Clinical Laboratory Tests
D. S. Young, D. W. Thomas, R. B. Friedman and L. C. Pestaner
This compilation of effects of drugs on laboratory action of drugs in humans. We should emphasize
tests has been developed from a computer-file of that we believe that the present list should be used
information that has been used to assist the as a guide for the interpretation of results. It
interpretation of abnormal test results in the should not be thought of as providing the correct
laboratories of the Clinical Pathology Department explanation for any abnormal data in any given
of the Clinical Center, National Institutes of situation. fh disease for which a drug was
Health. The computerized list contains entries of administered should al*ays be considered initially
both the normal physiological response to thera- as a source of abnormal results. Underlying disease
peutic drugs, as well as the effects of overdoses. processes and the concomitant administration of
We have not attempted a complete differentiation other drugs may have considerable influence on
between the two types of effects, nor have we the apparent action of one drug, so that the
separated rare effects from those that are common. reported effects of the drug may not occur or may
While most physicians are aware of the major be modified.
physiological or pharmacological effects of thera- Our file of effects of drugs on laboratory tests
peutic drugs on laboratory tests, many do not known as CLAUDE (computer list of anticipated and
know the minor effects of even some of the most unintended drug effects) is being expanded con-
widely used drugs. Few patient-care physicians tinually. This publication lists the first 9000
are aware of the possible influence of dngs entries into the system. rfhe entries are not
administered to patients on the analytical pro- necessarily the most important but represent the
cedures used to measure constituents of body results of our initial search of the literature.
fluids in the clinical laboratory. In the present Already many additional effects have been docu-
publication we include many common and less mented and these will be included in a later
common effects of drugs on laboratory tests that publication. We have expanded upon our original
have been reported in the literature. As source intention of including the effects of drugs only to
material we have used several recent books that include other factors that should be considered for
have been concerned with drug interactions as proper understanding of the significance of labora-
well as many publications on the clinical pharma- tory data. For example, we cite the modifying
cology and pathology of individual drugs. In most influences of certain foods, the menstrual cycle and
cases the effects have been observed in humans menopause in women, and the effects of activity
but we have included some findings from animal and change of posture in subjects from whom
studies when these have appeared to have some blood is obtained. These factors are often over-
relevance to the understanding of the mode of looked in the interpretation of laboratory data, yet
can alter the results of several tests to such an
extent that erroneous conclusions may be drawn
From the Clinical Pathology Department, Clinical Center,
about the state of health of an individual. It
National Institutes of Health, Bethesda, Maryland 20014. should be noted that several chemical compounds
betically by generic drug name. The second con- the effect was probably due to the analytical
tains the same information but is sorted alpha- procedure. If “V,” the effect occurred in the
betically by laboratory test. The format is the patient because of the pharmacological action of
same for both. the drug. The fifth colunm is an explanation of the
The first entry is the drug, chemical, or modi- effect. The final column lists a reference number.
fying condition. The second column consists of The reference directory includes-under the same
abbreviated entries for the fluid analyzed. The number-the authors, title, and journal citation of
single letter entry is explained in the abbreviation an article in which this effect was mentioned. The
and short-form directory. The third column con- abbreyiation and short-form directory lists all
tains the test made and whether the result was the nonconventional abbreviations used through-
increased, decreased, or unaffected by the corn- out this publication.
INDEX
1041 Introduction and Use of the Directories
1043 Acknowledgments
1044 Generic/Proprietary Drug Name Directory
1060 Abbreviation and Short-Form Directory
1063 Alphabetic Listing by Drug Name
1 166 Alphabetic Listing by Laboratory Test
1269 References
Acknowledgments
Many people have contributed to this publica- the data contributed by them have not yet been
tion by suggestions, verification of data, entry of incorporated into the published list). We have
information into the computer files, and assistance received assistance from Eli Lilly and Company,
in programming. In particular we would like to Knoll Pharmaceutical Company, J. B. Roerig
thank Dr. H. R. Gralnick, Dr. N. Gochman, (Pfizer), Abbott Laboratories, Armour Pharma-
Dr. A. E. Horvath, and Dr. D. P. Tschudy for ceutical Company, Riker Laboratories, Winthrop
reviewing data. D. F. L. Mitchell and Dr. D. C. Laboratories, Merck Sharpe and Dohme, G. D.
Cannon also gave assistance in obtaining back- Searle, Lakeside Laboratories, E. IL Squibb &
ground information. Mrs. Betty Smith, Mrs. Sons, Wyeth Laboratories, Smith Kline and
Carolyn Grubbs, and Mr. Douglas Ireland entered French, Upjohn Company, Syntex, Bristol Labora-
much of the data and Mr. J. F. Pestaner provided tories, Ciba-Geigy, U.S.V. Pharmaceutical Corp.,
valuable advice in programming. Miss Silja Meret Wallace Pharmaceuticals, and Schering Corp.
assisted with the proofreading. We are also grateful to Dr. J. F. Gallelli and the
We would like to acknowledge the cooperation of staff of the Clinical Center Pharmacy for their
several pharmaceutical houses (although much of help and encouragement.
OXANDROLONEt (ANAVAR)
OXAZEPAMt (SERAX)
OXAZOLIDINEDIONES (TRINETHADIONEt) (PARANETHADIONE*)
OXYMETHOLONEt (ADROYD) (ANADROL)
OXYPHENBUTAZONEt (TANDEARIL)
OXYPHENISATIN* (OXYPHENISATIN ACETATE) (PRULET) (EVASOF) (HYDROLOSE) (SYNCELAX) (URBALAX) (yb-LAX) (ISOCRIN) (DIALOSE)
OXYTETRACYCLIN!*(TERRA-CORTRIL) (OXYTETRACYCLINE CALCIUM) (OXYTETRACYCLINE HYDROCHLORIDE) (TERRAMYCIN) (TERRASTATIN)
PA I Nt
PAMAQUINEt(PAMAQUINE NAPHTHOATE) (PLASNOQUINE)
PA NCREOZY MI Nt
PANTOT HEN YL ALCOHOLt
PAPAVERINEt (PAPAVERINE HYDROCHLORIDE) (CERESPAN) (PAVABID) (VASOSPAN) (BLUPAV)
PARABROMDYLAMINE*(PARABRONDYLAMINE NALEATE) (DIMETANE)
PARALDEHYDN* (PAPAL)
PARAMETHADIONEt (PARADIONE)
PARAMETHASONEt (PARAMETHASONE ACETATE) (HALDRONE) (STENNEX)
PARASYMPATHOMINETIC ANINES*
PARATHION*
PARATHYROID EXTRACT* (PAROIDIN) (PARATHYROID INJECTION)
PARGYLINEt (PARGYLINE HYDROCHLORIDE) (EUTONYL)
PAROMOMYCIN t (PAROMOMYCIN SULFATE) (HUMATIN)
PECAZINEt
PENPIDINE*
PENETRAMATE*(PENETRANATE HYDRIIODIDE) (LEOCILLIN) (NEOPENIL) (ESTONYCIN) (!STOPEN)
PENICILLANINEt (CUPRIMINE)
PENICILLINt(AMPICILLINt) (METHICILLINt) (OXACILLINt) (CARBENICILLINt) (PHENOXYMETHYL PENICILLIN) (PHENETHICILLINt)
PENICILLIN*(PENICILLIN G) (CLOXACILLIN*) (DICLOXACILLINt) (NAFCILLIN*) (HETACILLIN*)
PENTAGASTRINt (PEPTAVLON)
PENTAMIDINE (PENTAMIDINE ISETHIONATE) (LOMIDINE)
PENTA QU INEt
PENTAZOCI NEt (TALWIN) (FOBTRAL) (P ENTA ZOCINE HYDROCHLORIDE) (PENTAZOCINE LACTATE) (FORTRALIN) (SOSEGON) (SOSIGON)
PENTOLINIUM*
PENTYLENETETRAZOL* (METRAZOL) (CENALENE-M) (CARDIA ZOL)
PERCHLORATE* (POTASSIUM PERCHLORATE)
PERHEXILENE*(PERHEXILEN! MALEATE) (PREXID)
PERIODATEt
PERMANGANATEt(POTASSIUM PERNANGANATE)
PEROXIDE* (HYDROGEN PEROXIDEt)
PERPHENAZINEt (TRILA EON)
PHENACEMIDE* (PHENURONE) (PHENYLACETYLUREA)
PHENAGLYCODOLt (DAVO-TRAN) (ULTRA N)
PHENAZOCINE*(PHENAZOCINE HYDROBRONIDE) (PRINADOL)
PHENAZOPYRIDINE*(PHENAZOPYRIDINE HYDROCHLORIDE) (AZO-NANDELAMINE) (DOLONIL) (DONNASEP) (PYRIDIUM) (THIOSULFIL)
PHENBLZINEt (PHENELZINE SULFATE) (NARDIL)
PHENETHICILLINt (SYNCILLIN)
PHENETURIDEt (PHENYLETHYLACETYL UREA)
PHENFORMINt (DBI) (PHENPORNIN HYDROCHLORIDE)
PHENINDIONEt(DANILONE) (HEDULIN) (ERIDIONE) (DINDEVAN)
PHENIODOL*
PHENIPRAZINEt (CATRON)
PHENMETRAZINEt (PHENMETRAZINE HYDROCHLORIDE) (PRELUDIN)
PHENOBARBITALt (BARBIPIL) (BARBITA) (ESK ABARB) (HYPNETTE) (LIXOPHEN) (SOLUBARB) (PHENOBARTITAL SODIUM) (LUMINAL)
PHENOLIC CONPOUN DS (PHENOLS*) (HEXACHLOROPHENE) (PHISOHEXt) (CHLOROTHYNOL) (CREOSOTEt) (CRESOLt)
PHENOLPHTHALEIN* (AGORAL) (CAROID) (EVAC-U-GEN) (KONDREMUL) (NOVALAX) (PHENOLAX)
PHFNOLSt (PHENOL DERIVATIVES) (LIQUIFIED PHENOL) (PHENOLATED CALAMINE LOTION) (CARBOLIC ACID)
PHRNOTHIAZINES* (CARPHENAZINEt) (FLUPEIENAZINEt) (VERPHENAZINEt) (PROCHLORPBRAZINEt) (TRIFLUOPERAZINE*)
PHENOTHIAZINES*(CHLOFPRONAZINEt) (NESORIDAZINE*) (THIORIDAZINEt) (ACETOPHENAZINE*) (BUTAPERIZINE*)
PHENOTHIAZINESt (PRONETHAZINEt) (PROPIOMAZINE) (PRONAZINEt) (TRIFLUOPERAZINE*) (NETHOTRINEPRAZINEt) (TRIFLUPRONAZINE*)
PHENOTHIAZINESt(THIOPROPAZATE*) (PIPERACETAZINE*) (METHDILAZINE) (TRIMEPRAZINEt)
PHENOXYBENZAMINEt (DIBENZYLINE)
DEC
V
V
V
THERAPEUTIC
IMPAIRS
THERAPEUTIC
GOAL
ABSORPTION
EFFECT
(?INC
OF
BIND
IRON
OF BILE
. SALTS IN GUT) P0465
P0540
P0596
CHOLESTYRAMINE S SCOT INC V FEW CASES REPORTED PROB NOT HEPATOTOXICITY P0467
CHOLLSTYRANINL S SGPT INC V FEW CASES REPORTED PPOB NOT HEPATOTOXICITY P0467
CHOLESTYRAMINE S THYROXINE (T14) DEC V DECREASED INTESTINAL ABSORPTION OF THYROXINE P0907
CHOLESTYRANINE S TOTAL LIPIDS DEC V LOWERS BILE ACIDS BY IONIC BINDING R0620
CI4OLESTYRANINE S TRIGLYCERIDES DEC V THERAPEUTIC EFFECT P0596
CHOLFSTYPANINT S TRIGLYCERIDES INC V MECHANISM OBSCURE (MAY OCCUR IN DIABETICS) P0504
CHOINSTYPAMINE S VITAMIN A Z V ABSORPTION NOT SIGNIFICANTLY IMPAIRED P0657
CEOLESTYRAMINE U CALCIUM INC V BINDS HEAVY METALS RC299
CH0LINrFGICS S ANYLASE INC V CAUSE SPASM OF SPHINCTER OF ODDI P0042
CHOLIt4TPGICS S BILIRUBIN INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P0204
CHOLINEP.GICS S HSP RETENTION INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P02014
CHOLINERGICS S LIPASE INC V IMPAIRED EXCRETION-SPASM OF SPHINCTER OP ODDI P0384
CHOLINERGICS S SGCT INC V IMPAIRED EXCRETION DUE TO SPASM OF SPHINCTER P02014
HPYSAROBIN U URINALYSIS COLOR INC N OXIDATION PRODUCT COLORS ALKALINE URINE RED RC384
CHPYSAROBIN U URINALYSIS PROTEIN INC V KIDNEY IRRITATION BY METABOLITE R0C26
CINCHOPHEN B WHITE CELL COUNT DEC V LEUKOPENIA OP AGRANULOCYTOSIS MAY OCCUR P0658
ZIN2HOPHEN S ALKALINE PHOSPHATASE INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0620
CINHOPHFN S BILIRUBIN INC V NAY CAUSE HYPERSENSITIVE CHOLESTASIS R062C
CINCHOPHEN S BSP RETENTION INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
INCHOPHIN S CEPHALIN FLOCCULATION INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINCH0PHN S CHOLESTEROL INC V MAY CAUSE INTRAHEPATIC CHOLESTASIS P0405
CINCHOPHEN S SCOT INC V MAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINCHOPHEN S SGPT INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINCHOPHEN S THYNOL TURBIDITY INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) R0620
CINCHOPHEN S URIC ACID DEC V URICOSURIC ACTION P0620
CINCHOPHEN U URINALYSIS BILE INC V NAY CAUSE HEPATOTOXICITY (VIRAL-HEPATITIS LIKE) P0620
CINHOPHEN U URINALYSIS COLOR INC N RED BROWN P0620
CINCHOPHEN U URINALYSIS SUGAR INC M ACTS AS A REDUCING SUBSTANCE P0654
2ITPATFS B PH DEC N SIGNIFICANT EFFECT OF NA CITRATE AS ANTICOAGULANT R0181
CITRATES B PH DEC V SIGNIFICANT ACID SHIFT PRODUCED P0354
CITRATFS B PH INC V RESTORES BICARB RESERVE, MAY CAUSE ALKALOSIS P0026
CITRATES S AMYLASE DEC N INHIBITION OF ENZYME ACTIVITY P0635
TTRATFS S CALCIUM DEC V COMPLEXES CALCIUM P0620
CITRATES S HBD Z N NO EFFECT ON ACTIVITY P0779
CITHATES S IONIZED CALCIUM DEC V COMPLEXES CALCIUM (EFFECT OP TRANSFUSIONS) P0743
CITRATES S MAGNESIUM DEC V COMPLEXES MG (MAY OCCUR WITH BLOOD TRANSFUSIONS) P0094
ITRATTS S PH DC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
ITRATaS S URIC ACID INC V ANTAGONISM OF UPICOSUPIC EFFECT P0355
CITATNS U URIC ACID DEC V ANTAGONISM OF UPICOSURIC EFFECT R0355
CITRAT?S U VOLUME INC V WEAK DIURETIC EFFECT R0026
CLTNDAMYCIN B EOSINOPHILS INC V OCCASIONAL ALLERGIC RESPONSE P0735
CLINDANYCIN B WHITE CELL COUNT DEC V MAY CAUSE AGRANULOCYTOSIS RC736
CLINDANYCIF S ALKALINE PHOSPHATASE INC V TRANSIENT ABNORMALITY NOTED P09149
CLINOAMYC:N S BILIRUBIN INC V OCCURS ESPECIALLY IF PREEXISTING LIVER DISEASE P0735
CLINDAMYCIr S SCOT INC V TRANSIENT ABNORMALITY NOTED P0949
CLNDAMYCIN S SGPT INC V MILD TRANSIENT RISES SEEN P0735
LIOQUINOL B NEUTROPHILS INC V TOXIC EFFECT REPORTED P0921
CLI000INOL S PBI INC N IS AN ORGANIC IODINE COMPOUND P0596
CLO?IBRAT 3 EUGLOBULIN LYSIS TIME DEC V REPORTED OBSERVATION P0657
LOFIBPATE P WHITE CELL COUNT DEC V MAY CAUSE LEUKOPENIA P0784
CLOF IPHATS ? BILE ACIDS DEC V AFTER TWO WEEKS TREATMENT SIGNIFICANT FALL P0668
CLOFIBRATE F NEUTRAL STEROIDS DEC V AFTER TWO WEEKS TREATMENT FALL OBSERVED P0668
CLOFIBTATE P FIERINOGEN DEC V REPORTED OBSERVATION IN SOME CASES RC195
CLOFIBSAT P PROTHHOMBIN TIME INC V DISPLACES ANTICOAGULANTS FROM BINDING PROTEIN RO7QJ
CLOFIBPAT S ACID PHOSPHATASE TOTAL INC V REPORTED EFFECT (?MECHANISM) P0299
:LoFIBRAT S ALKALINE PHOSPHATASE INC V HEPATOTOXIC EFFECT R0620
CLOFIBRAT S ALPHA-TOCOPHEROL DEC V ?INHIBITS SYNTHESIS OF CARRIER LIPOPROTEIN P0978
8
ETHER H PR DEC V METABOLIC ACIDOSIS ESP IN CHILDREN 90026
ETHOXAZOLANIDE B PH DEC V NAY CAUSE METABOLIC ACIDOSIS 90596
FRUCTOSE B PH DEC
PH DEC VV ASSOCIATED WITH LACTIC ACIDOSIS 90227
ISONIAZID LARGE DOSES MAY PRODUCE SEVER! ACIDOSIS 30384
MAFENIDE H PH DEC V IF RESP IMPAIRMENT AS REDUCED RENAL BUFEERING P0048
MDA B PR DEC V RESPIRATORY ACIDOSIS R0778
METHANOL H PH DEC V CAUSES ACIDOSIS P0620
OXALATES B PH DEC N SIGNIFICANT EFFECT OF NH4 OXALATE AS ANTICOAGULANT 90181
PAR ALDEHYDE H PH DEC V ACIDOTIC ACTION P0620
PHENFOPMIN H PH DEC V ACIDOSIS CAN OCCUR P0355
STORAGE OF SAMPLE B PH DEC N IF ANAEROBIC STORAGE AT 37 DEG OR 2H AT ROOM TEMP P1001
TETRA CYCL INC B PH DEC V MAY CAUSE ACIDOSIS WITH RENAL IMPAIRMENT P0596
TUBOCURARINE B PH DEC V LARGE DOSE EFFECT WITH PROLONGED RECOVERY 90596
XYLITOL H PH DEC V PRONOUNCED METABOLIC ACIDOSIS IN MANY PATIENTS R0924
CITRATES S PH DEC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
EDTA S PH DEC N IN VITRO ADDITION OF NA SALT TO PLASMA/SERUM P0035
AC ETA TES H PH INC V ALKALINIZING ACTION DUE TO RAPID METABOLISM 903814
ACETYLSALICYLIC AC B PR INC V INITIAL RESPIRATORY ALKALOSIS P0957
ANTACIDS B PR INC V MAY CAUSE OCCASIONAL METABOLIC ALKALOSIS P0026
CITPATES B PH INC V RESTORES BICAPH RESERVE, MAY CAUSE ALKALOSIS P0026
ETHACRYNIC ACID H PH INC V HYPOCHLOREMIC ALKALOSIS MAY OCCUR P09140
GLUTAMIC ACID H PH INC V NA SALT MAY CAUSE ALKALOSIS P0026
HE AT H PH INC M INC 0.015 PEP DEGREE (MAY ALSO AFFECT BUFFERS) P0181
HYPERVENTILATION B PH INC V DUE TO RESPIRATORY ALKALOSIS 90836
LACTATE H PH INC V USED IN TREAT OF METABOLIC ACIDOSIS 30026
LICORICE H PH INC V MAY CADS! ALKALOSIS 90596
MAFENIDE H PH INC V USUAL FINDING WITH R!SP ALKALOSIS 30048
MEALS H PR INC V EFFECT OF METABOLIC ALKALOSIS 30846
MERCURIAL DIURETICS B PH INC V MAY CAUSE SYSTEMIC ALKALOSIS ESP IF HYP3CHLOPEMIA P0384
OXALATES H PH INC N OCCURS WITH NA OR K OXALATES AS ANTICOAGULANTS 90181
SILVER H PH INC V OBSERVED AFTER SILVER NITRATE ANTISEPSIS 90657
SODIUM BICARBONATE H PH INC V AFFECTS ACID-BASE BALANCE IN VIVO R0620
STORAGE OF SAMPLE B PR INC N IF SAMPLE EXPOSED TO AIR 91001
TROMETHAMINE B PH INC V CAN CORRECT METABOLIC OP HYPEPCAPNIC ACIDOSIS 90782
co: ACLAND JD
THE INTERPRETATION OF TEE SERUM PROTEIN BOUND IODINE: A REVIEW
J CLIN PATHOL 24, 187 (1971)
CC5 ATOCELLA G, BILLING BN
EFFECT OF DRUGS ON THE HPATIC TRANSPORT OF BILIRUBIN
IN THEPAPEUTIC AGONTS AN) THE LIVER, MCINTYRE N, SHERLOCK S (LOS) BLACKWELL, OXFORD (1965)
C#{149}006
ADAMS PG, HARRISON OR, SCOTT P
THE DLVELOPNENT OF CADMIUM INDUCED PROTEINURIA, IMPARIED RENAL FUNCTION AND OSTEOMALACIA
QUART C MED 38, 1425 (1969)
CCC7 A3NITT 21
HYPOGLYCEMIC ACTION OF MONOAMINE OXIDASE INHIBITORS (NAOI’S)
DIABETES 17, 628 (19#{128}8)
0008 AGGELEP PM, O’REILLY PA, LEONG L ET AL
?OTENTIATION OF ANTICOAGULANT EFFECT OF WARFARIN BY PHENYLBUTAZONE
EW ENGL J NED 27#{128},496 (1967)
00:9 AUS ES, GOLDBERG N
PNAL MECHANISMS OF THE NATBIURETIC AND ANTIPHOSPHATURIC EFFECTS OF TRIFLOCIN - A NEW DIURETIC
J LAB CLIN MED 76, 283 (1970)
OC1C AH ROBINS
MANUFACTURER’ S LITERATURE ON DOPRAM
14C7 CUMMINGS DP, RICEMOND VA 23220
0011 AITKF.W 3M, HART D1, SMITH DA
TF EFFECT 02 LONG-TERM MESTRANOL ADMINISTRATION ON CALCIUM AND PHOSPHORUS HONEOSTASIS IN OOPHOPECTONIZED WOMEN
OLIN SCI 41, 233 (1971)
0012 AJTUNIEWICZ AB, GRAINGEP J, SCHEUER P3, SHERLOCK S
JAUNDICE DUE TO IPRINDOLE
GUT 12, 705 (1971)
C013 AL-HUJAJ N, SCHONTHAL H
HYPERUBICEMIA AND LEVODOPA
NEW ENGL J MED 285, 859 (1971)
OCILL ALPC0N-SEGOViA 0, WAKIM KG, WORTHINGTON 3W, WARD LI
CLINICAL AND EXPERIMENTAL STUDIES ON THE HYDRALAZINE SYNDROME
!EDICIN 46, 1 (1967)
0015 ALARCON-SEGOVIA D, FISHLEIN E, ALCALA H
ISONIAZIL ACETYLAIION RATE AND DEVELOPMENT OF ANTINUCLEAR ANTIBODIES UPON ISONIAZID TREATMENT
ANTH!ITIS PHEUM 14, 71.8 (1971)
316 ALBERT N, STANSELL MO
VASCULAR SYMPTOMATIC RELIEF DURING ADMINISTRATION OF ETHYLCHLOROPHENOXYISOBUTYRATE (CLOFIBRATE)
METJBOLISM 18, 635 (1969)
0017 ALEXANDER FL JR
EVALUION OF AN AUIOATIC CALCIUM TITPATOR
OLIN CHEN 17, 1171 (1971)
0018 ALLISON SP, CHAMBERLAIN NJ, MILLER JE, FERGUSON 9, GILLETT AP,BEMAND BV, SAUNDERS PA
LFFECTS OF PROPRANOLOL ON BLOOD SUGAR, INSULIN AND FREE FATTY ACIDS
DIABFTOLOGIA 5, 339 (1969)
0019 ALMEN I
A STEEPING DEVICE FOP SELECTIVE ANGIOGRAPHY AND SOME VASCULAR AND ENZYMATIC REACTIONS OBSERVED
ACTA RADIOL (SUPPL) 260, (1966)
‘OC2C ALMN T
TOXICITY OF RADIO CONTRAST AGENTS
IN INTERNATIONAL ENCYCLOPEDIA OF PHARMACOLOGY AND THERAPEUTICS VOL2, PERGAMON PRESS, NEW YORK (1971)
0021 AMA COUNCIL ON DRUGS
NEW DRUGS
1967 EDITION CHICAGO ANEBICAN MEDICAL ASSOCIATION (1967)
0222 AMA COUNCIL OF DRUGS
A COPPER-CHELATING AGENT: PENICILLANINE (CUPRIMINE)
3 AMER MED ASS 189, 847 (1964)
0023 AMA COUNCIL ON DRUGS
A NEW ANTIBIOTIC- LINCONYCIN
3 AFR !!FD ASS 194,545 (1965)
0C24 AMA COUNCIL ON DRUGS
REGISTRY ON ADVERSE REACTIONS
A’IER ‘ED ASSOC (1964)
3025 AMA COUNCIL ON DRUGS
FISTBY ON ADVERSE REACTIONS, TABULATION OF REPORTS - PANEL ON HEMATOLOGY
A’E9 MED ASSOC JULY (1964)
0C26 AMA COUNCIL ON DRUGS
A?IA DRUG EVALUATIONS
AMA 535 NORTH DEARBORN ST, CHICAGO, ILL 60610
2027 AVADO? E, SALVATOPE AC
SERUM GLUTAMIC OXALOACETIC TRANSAMINASE ACTIVITY, REVISED MANUAL AND AUTOMATED METHODS USING DIAZONIUM DYES
AMER 3 CLIN PATHOL 55, 686 (1971)
0028 AVBPUS JL, SCHINERT G, LAJOS TZ,ANBRUS CM, MINK IB, LASSNAN HB, MOORE PH, NELZER 3
EFFECT OF ANTIFIBSINOLYTIC AGENTS AND ESTROGENS ON BLOOD LOSS AND BLOOD COAGULATION FACTORS
3 MCD 2, 65 (1971)
0029 AMERICAN HOSPITAL FORMULARY SERVICE
AMERICAN HOSPITAL FORMULARY SERVICE,
AEERICAN SOCIETY OF HOSPIIAL PHARMACISTS, WASHINGTON, DC
OC3C AMERY A, CONWAY 3
A CRITICAL REVI!W OF DIAGNOSTIC TESTS FOR PHEOCHEOMOCYTOMA
AMER HFART 3 73, 129 (1967)
CLINICAL”YF’ .#{149}
,
0751 PRETTY NM, GOSSELIN G, OOLPRON G, LONG LA
AGRANULOCYTOSIS: A REPORT OF 30 OASES
CANAD NED ASS 3 93, 1058 (1965)
0752 PRICE NL
CIPCULATING ADRENALINE AND NORADRENALINE DURING DIETHYL-ETHER ANAESTNSIA IN MAN
OLIN SOT 16, 377 (1957)
0753 PROCTOR FA, BARTON FL
POLYOBIC ACUTE RENAL FAILURE AFTER METHOXYFLURANE AND TETRACYCLINE
BRIT MED 3 4, 661 (1971)
0734 PRO?? RP, STILLMAN JS
AGRANULOCYTOSIS AND HYDROXYOHLOROQUINE
NEW ENGL J MED 277, 492 (1967)
0755 PUL’KINEN NO, WILLMAN K
SERUM INORGANIC PHOSPHATE DUPING OPAL CONTRACEPTIVE THERAPY
ANN CHIP GYNEC FENN 57, 172 (1968)
0756 PYBUS 3, BOWERS GN JR
SERUM LITHIUM DETERMINATION BY ATOMIC ABSORPTION SPECTROSCOPY
STAND METH OLIN CHEM 6, 189 (1970)
0757 QUAGLIANA 3M
EFFECT OF TOPICAL POVIDONE-IODINE (BETADINE) ON SERUM PROTEIN-BOUND IODINE
3 CLIN ENDOCRINOL 23, 395 (1963)
0758 RAAB WP
THE DIAGNOSTIC VALUE OF URINARY ENZYME DETERMINATIONS
OLIN 011KM 18, 5 (1972)
0759 PABINOWITZ D, MERINEF TO, NELSON 3K, SCHULTZ RB, BURGESS JA
IN GROWTH HORMONE INTERNATIONAL CONGRESS SERIES NO 158,
PECILE A, MULLER E! (EDS) EXCERPTA MEDICA FOUNDATION, AMSTERDAM (1968)
0760 RACE TT, PARS IC, FALOON WW
INTESTINAL MALABSORPTION INDUCED BY ORAL COLCHICINE COMPARISON WITH NEOMYCIN AND CATHARTIC AGENTS
AMER 3 NED Sd 259, 32 (1970)
0761 RADCLIFP P3, WILTON NM, DONNELLY GL
CLOPAMIDE (BRINALDIX), A NEW DIURETIC AGENT: DURATION OF ACTION AND DOSAGE RESPONSE
CURRENT THERAP RES 10, 103 (1968)
0762 PAMSAY ID
CARBAMAZEPINE-INDUOED JAUNDICE
BRIT MED 3 4, 155 (1967)
0763 PA?OPOPT S FT AL
HYPOPROTHROMBINEMIA AFTER SALICYLATE ADMINISTRATION IN NAN AND RABBITS
PROC SOC EXP BIOL NTD 53, 40 (1943)
0764 PECHENBERG MN
PHENYLBUTAZONE
EDWARD ARNOLD LTD LONDON (1962)
0765 REEVES DS
SULFAMETHOXAZOLE/TRIMETHOPRIM: THE FIRST TWO YEARS
3 OLIN PATHOL 24, 430 (1971)
0766 REINER N, CHEUNG HL
XYLOSE
STAND METH OLIN CHEM 5, 257 (1965)
0767 PEINHAPD’T DJ III, TAUSIG I, ALVAREZ B
SERUM CHOLESTEROL ELEVATION WITH TRIPLUORPERAZINE (STELAZINE) THERAPY
DELAWARE MED 3 34, 318 (1962)
0769 PEINKEN L, HOHENAUER L, ZIEGLER EE
ACTIVITY OF RED CELL GLUTAMIC OXALOACETIC TRANSAMINASE IN EPILEPTIC CHILDREN UNDER ANTIEPLETIC TREATMENT
CLIN CHIN AOTA 36, 270 (1972)
0769 REIO L, WETTERBEPG L
FALSE PORPHOBILINOGEN PEACTIONS IN THE URINE OF MENTAL PATIENTS
J AMER NED ASS 207, 148 (1969)
0770 REISS E, CANTERBURY 3M, BEPCOVITZ MA, KAPLAN EL
POLE OF PHOSPHATE IN THE SECRETION OF PARATHYROID HORMONE IN MAN
3 OLIN INVEST 49, 2146 (1970)
0771 REMP DG
URIC ACID (URICASE)
STAND METH OLIN CHEM 6, 1 (1970)
0772 RENNIF 1DB, KEEN H
EVALUATION OF CLINICAL METHODS FOR DETECTING PROTEINURIA
LANOET 2, 489 (1967)
0773 PEUBI PC, VORBUGER C, BUTIKOFER F
A COMPARISON OF THE SHORT-TERN AND LONG-TERM HAENODYNAMIC EFFECT OF ANTIHYPERTENSIVE DRUG THERAPY
IN CATAPRES IN HYPERTENSION, CONOLLY ME (ED) BUTTERWOPTH, LONDON (1970)
074 REYNOLDS TB, PELLE HO
EFFECTS OF A NEW DIURETIC ANIPRAMIDINE (MK 870) IN PATIENTS WITH CIRRHOSIS AND ASOITES
OLIN RES 14, 1814 (1966)
0775 REYNOLDS EN, MILNEP G, MATHEWS DM, CHANARIN I
ANTICONVULSANT THERAPY, MEGALOBLASTIC HAENOPOIESIS AND FOLIO ACID METABOLISM
QUART 3 MED 35, 521 (1966)
0776 REYNOLDS TB, PETERS RL, YAMADA S
CHRONIC ACTIVE AND LUPOID HEPATITIS CAUSED BY A LAXATIVE, OXYPHENISATIN
NEW ENGL 3 NED 285, 513 (1971)
0777 RICE EW, LUKASIEWICZ DR
INTERFERENCE OF BROMIDE IN ZAK FEOL3 SULFURIC ACID CHOLESTEROL METHOD AND MEANS OF ELIMINATING THIS INTERFERENCE
OLIN CHEM 3, 160 (1957)
0778 RICHARDS NO, BORGSTEDT HH
NEAR FATAL REACTION TO INGESTION OF THE HALLUCINOGENIC DRUG NDA
3 AMER MED ASS 218, 1826 (1971)
0779 RICMTERICH B
CLINICAL CHEMISTRY - THEORY AND PRACTICE
KARGER, BASEL 1969
0780 RIDDOCH D
GASTPITIS AND L-DOPA
SPIT lIED 3 1, 53 (1972)